Table 2.
AUCs with standard errors for base models and kallikrein panel models for high grade cancer in men with PSA 10-25 and in men with positive DRE, by cohort.
| PSA 10 – 25 ng/ml | Positive DRE | |||||
|---|---|---|---|---|---|---|
| Cohort | Base model | Kallikrein panel | Difference (95% CI) | Base model | Kallikrein panel | Difference (95% CI) |
| Göteborg Unscreened7 | 0.765 (SE 0.088) | 0.835 (SE 0.056) | 0.070 (−0.043, 0.184) | 0.719 (SE 0.062) | 0.762 (SE 0.055) | 0.043 (−0.051, 0.136) |
| Göteborg Previously Screened*6 | Excluded | Excluded | Excluded | 0.671 (SE 0.075) | 0.747 (SE 0.070) | 0.076 (−0.028, 0.181) |
| OPKO*4 | 0.627 (SE 0.057) | 0.871 (SE 0.037) | 0.245 (0.133, 0.356) | 0.733 (SE 0.035) | 0.855 (SE 0.026) | 0.122 (0.066, 0.177) |
| ProtecT12 | 0.652 (SE 0.026) | 0.778 (SE 0.021) | 0.126 (0.074, 0.178) | Excluded | Excluded | Excluded |
| Rotterdam*5, 8 | 0.760 (SE 0.034) | 0.881 (SE 0.023) | 0.121 (0.068, 0.174) | 0.751 (SE 0.022) | 0.832 (SE 0.019) | 0.081 (0.049, 0.113) |
| Rotterdam Repeat Biopsy*10 | 0.615 (SE 0.115) | 0.882 (SE 0.044) | 0.267 (0.099, 0.436) | 0.676 (SE 0.083) | 0.833 (SE 0.059) | 0.157 (0.028, 0.285) |
| Tarn*9 | 0.795 (SE 0.119) | 0.955 (SE 0.052) | 0.159 (−0.082, 0.400) | 0.589 (SE 0.067) | 0.763 (SE 0.054) | 0.175 (0.075, 0.274) |
| UPCA*13 | 0.702 (SE 0.046) | 0.791 (SE 0.037) | 0.089 (0.011, 0.166) | 0.703 (SE 0.040) | 0.776 (SE 0.034) | 0.073 (0.009, 0.137) |
| Fixed effects meta-analytic Estimate (95% CI) | 0.690 (0.657, 0.724) | 0.838 (0.814, 0.861) | 0.128 (0.098, 0.159) | 0.724 (0.694, 0.754) | 0.820 (0.795, 0.844) | 0.092 (0.069, 0.115) |
| Random effects meta-analytic Estimate (95% CI) | 0.696 (0.646, 0.745) | 0.851 (0.803, 0.898) | 0.133 (0.092, 0.174) | 0.720 (0.686, 0.753) | 0.815 (0.786, 0.845) | 0.094 (0.068, 0.119) |
| Heterogeneity p value | p=0.15 | p=0.003 | p=0.2 | p=0.4 | p=0.3 | p=0.4 |
*
Independent validation.